Reform at Risk — Mandating Participation in Alternative Payment Plans

Scott Levy

Nicholas Bagley
*University of Michigan Law School*, nbagley@umich.edu

Rahul Rajkumar

Available at: [https://repository.law.umich.edu/articles/1997](https://repository.law.umich.edu/articles/1997)

Follow this and additional works at: [https://repository.law.umich.edu/articles](https://repository.law.umich.edu/articles)

Part of the [Administrative Law Commons](https://repository.law.umich.edu/articles), [Health Law and Policy Commons](https://repository.law.umich.edu/articles), and the [Insurance Law Commons](https://repository.law.umich.edu/articles)

Recommended Citation


This Article is brought to you for free and open access by the Faculty Scholarship at University of Michigan Law School Scholarship Repository. It has been accepted for inclusion in Articles by an authorized administrator of University of Michigan Law School Scholarship Repository. For more information, please contact mlaw.repository@umich.edu.
Reform at Risk — Mandating Participation in Alternative Payment Plans
Scott Levy, B.A., Nicholas Bagley, J.D., and Rahul Rajkumar, M.D., J.D.

In an ambitious effort to slow the growth of health care costs, the Affordable Care Act created the Center for Medicare and Medicaid Innovation (CMMI) and armed it with broad authority to test new approaches to reimbursement for health care (payment models) and delivery-system reforms. CMMI was meant to be the government’s innovation laboratory for health care: an entity with the independence to break with past practices and the power to experiment with bold new approaches. Over the past year, however, the Department of Health and Human Services (HHS) has quietly hobbled CMMI, imperiling its ability to generate meaningful data on strategies for reducing spending on Medicare and Medicaid.

The controversy involves the abrupt termination (or, in one case, narrowing) of several “mandatory” payment programs. When it created CMMI, Congress aimed to overcome the obstacles that had impaired some of the earlier payment-reform efforts undertaken by the Centers for Medicare and Medicaid Services (CMS). In particular, CMMI was given the power to waive any part of the Medicare statute, parts of the Medicaid statute, and various anti-fraud provisions when designing its payment models. To insulate CMMI from the vagaries of the annual appropriations process, Congress supplied the agency with
that “works” for volunteer organizations might not work for other organizations, which is why voluntary programs don’t always provide insight into whether a payment approach ought to be rolled out on a nationwide basis.

Making participation in a payment program mandatory allows the agency to correct for these selection effects. But such programs must be designed carefully. Conscripting all providers would eliminate the opportunity to have a control group, thus hampering evaluation of a payment model’s causal effects. There are also problems associated with enlisting a randomly selected group of providers: forcing one provider — and not its competitor — into a payment program could put one or the other at a competitive disadvantage and could result in odd market dynamics. Given the choice, some patients might opt to go to a hospital that wasn’t participating in a CMMI program, for example. This type of patient-level selection could skew evaluation. The better approach — and the one that CMMI has embraced — is to enroll all providers in randomly selected geographic areas in a given payment program, allowing providers in other areas to serve as controls. Such mandatory programs were also designed to enlist a large, diverse sample of providers in order to yield generalizable results.

In 2015, CMMI chose hospitals in specified regions to test bundled payments for hip and knee replacements. In 2016, the agency established a similar project for hip and femur fractures and for cardiac events. Mandatory payment programs were lauded in some quarters but provoked strong, organized opposition in others. Nearly 200 members of Congress and several provider organizations (including the American Medical Association, the American Academy of Orthopaedic Surgeons, and the Federation of American Hospitals) decried mandatory payment programs, with some calling them heavy-handed and others alleging illegality.

They found a receptive audience in President Donald Trump’s first HHS Secretary, Tom Price, a former orthopedic surgeon and an unspiring critic of mandatory payment programs. On taking office, Price paused the Obama-era mandatory bundled-payment programs; some months later, he formally ended the programs for cardiac events and hip and femur fractures. HHS also sharply reduced the size of the program for hip and knee replacements, draining the study of much of its statistical power. Simultaneously, the agency announced that it would recommit itself to voluntary payment programs.

The backpedaling is unfortunate and unnecessary. Mandatory programs are crucial tools for evaluating new payment models, and they stand on a solid legal foundation. When Congress vested CMMI with broad authority to test new payment models, it emphasized that it wanted the agency “to determine the effects of applying such models . . . on program expenditures . . . [and] quality of care.” Why ask CMMI to measure the effects of new models, but deny it the authority to adopt the best available scientific methods? Even more fundamentally, Congress authorized HHS to adopt successful payment models nationwide. It would not have delegated to CMMI the extraordinary power to reshape Medicare and Medicaid while prohibiting the agency...
from amassing the highest-quality evidence about which models are effective.

In addition, CMMI’s authorizing statute prohibits the courts from reviewing the agency’s “selection of organizations, sites, or participants.” This provision also reinforces the conclusion that Congress meant to allow CMMI to insist on participation. What good would it do to prohibit volunteers from suing over their “selection”? They have, after all, volunteered. The prohibition makes sense only if Congress expected that some providers might be required to participate.

Statements from the nonpartisan Congressional Budget Office (CBO) confirm that Congress anticipated mandatory payment programs. In response to a question from then-Congressman Tom Price, the CBO wrote that its initial budget projections for CMMI assumed that the center would conduct demonstrations using a broad array of innovative approaches and that it “was not surprised when CMMI designed a demonstration in which participation was mandatory because that approach offers several important advantages.”

If the legal objections to mandatory payment programs are insubstantial, the federal government’s decision to abandon such programs is difficult to defend. Without question, they are critical to developing robust evidence on strategies for cutting spending and improving quality. Current HHS Secretary Alex Azar testified before Congress that he is open to mandatory participation in new payment models. We believe he should follow through — or we will lose a key tool for learning new ways of constraining health care spending.

Disclosure forms provided by the authors are available at NEJM.org.

From Yale Law School, New Haven, CT (S.L.); University of Michigan Law School, Ann Arbor (N.B.); and Blue Cross Blue Shield of North Carolina, Durham (R.R.).


DOI: 10.1056/NEJMp1800483
Copyright © 2018 Massachusetts Medical Society.